Skip to main content
Finland
Global Fin Swe Nor Den Ger Cze Svk Pol Hun Nld Bel (nl) Bel (fr) USA
  • Aidian – Your aid in diagnostics
  • Tuotteet
  • Tietoa meistä
  • Uutiset
  • Laitehuolto
  • Antibioottiresistenssi
  • Aidian Academy
  • Asiakastarinoita
  • Messut ja tapahtumat
Ota yhteyttä Hae
Logo
Ota yhteyttä
  • Vieritestaus
  • Mikrobiologia
  • Molekyylimikrobiologia
  • Hygieniavalvonta
  • RIA / kollageenit
  • Hengitystieinfektiot
  • Muut
Vieritestaus
  • QuikRead go vieritestijärjestelmä
  • QuikRead 101
  • Certest
  • Dipro LH ja Dipro hCG
  • Nova Biomedical
  • bioLytical Laboratories INSTI
  • ImmunoFLOW Mycoplasma pneumoniae
  • SD BIOSENSOR STANDARD Q
  • ACRO™ Biotech
  • microINR
  • Hangzhou AllTest Biotech
Lue lisää
QuikRead go
  • QuikRead go Plus Instrument
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go CRP
  • QuikRead go CRP+Hb
  • QuikRead go wrCRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go iFOBT
  • QuikRead go Strep A
  • QuikRead go -tarvikkeet
QuikRead go
Mikrobiologia
  • Uricult
  • Uricult Vet
  • Cultura M
  • MIKROGEN serologia
  • Meridian Immunoassays
  • Meridian Curian®
Lue lisää
Molekyylimikrobiologia
  • ELITech Molecular Diagnostics
  • Meridian Revogene®
  • Meridian Alethia®
  • MIKROGEN molecular diagnostics
  • SD BIOSENSOR STANDARD M10
Lue lisää
Hygieniavalvonta
  • Easicult
  • Hygicult
  • Clean Card PRO
Lue lisää
RIA / kollageenit
  • UniQ
Lue lisää
Muut
  • Grifols Promonitor®
  • Dipro Druglab -huumetestit
  • Instant-View Multi Drug -huumetestit
Lue lisää
  • Historiamme
  • Hallitus ja johto
  • Aidianin kotimaan myynti
  • Vastuullisuus
  • Kulttuuri
  • Työpaikat
  • Uutiset
  • Tuoteuutiset
  • AMR
  • Tapahtumat
  • Stories from customers
  • COVID-19
  • QuikRead go Instrument -huoltolomake
  • Usein kysyttyjä kysymyksiä
  • Yhteystiedot
  • Tietoa C-reaktiivisesta proteiinista (CRP)
  • CRP alahengitystieinfektioissa
  • Lisämateriaalia
  • QuikRead go CRP -tuotteet
  • Hyödyllisiä linkkejä
  • Yleisesti
  • Tuotetiedot
  • Kurssit
  • Markkinointi- ja myyntimateriaalit
  • Usein kysytyt kysymykset
  • Unihygienia: tyynyjen ja vuodevaatteiden puhtauden seuranta
Logo
Ota yhteyttä Sulje
  • Tuotteet
    • Vieritestaus
      • QuikRead go vieritestijärjestelmä
      • QuikRead 101
      • Certest
      • Dipro LH ja Dipro hCG
      • Nova Biomedical
      • bioLytical Laboratories INSTI
      • ImmunoFLOW Mycoplasma pneumoniae
      • SD BIOSENSOR STANDARD Q
      • ACRO™ Biotech
      • microINR
      • Hangzhou AllTest Biotech
    • Mikrobiologia
      • Uricult
      • Uricult Vet
      • Cultura M
      • MIKROGEN serologia
      • Meridian Immunoassays
      • Meridian Curian®
    • Molekyylimikrobiologia
      • ELITech Molecular Diagnostics
      • Meridian Revogene®
      • Meridian Alethia®
      • MIKROGEN molecular diagnostics
      • SD BIOSENSOR STANDARD M10
    • Hygieniavalvonta
      • Easicult
      • Hygicult
      • Clean Card PRO
    • RIA / kollageenit
      • UniQ
    • Hengitystieinfektiot
    • Muut
      • Grifols Promonitor®
      • Dipro Druglab -huumetestit
      • Instant-View Multi Drug -huumetestit
  • Tietoa meistä
    • Historiamme
    • Hallitus ja johto
    • Aidianin kotimaan myynti
    • Vastuullisuus
    • Kulttuuri
    • Työpaikat
  • Uutiset
    • Uutiset
    • Tuoteuutiset
    • AMR
    • Tapahtumat
    • Stories from customers
    • COVID-19
  • Laitehuolto
    • QuikRead go Instrument -huoltolomake
    • Usein kysyttyjä kysymyksiä
    • Yhteystiedot
  • Antibioottiresistenssi
    • Tietoa C-reaktiivisesta proteiinista (CRP)
    • CRP alahengitystieinfektioissa
    • Lisämateriaalia
    • QuikRead go CRP -tuotteet
    • Hyödyllisiä linkkejä
  • Aidian Academy
    • Yleisesti
    • Tuotetiedot
    • Kurssit
    • Markkinointi- ja myyntimateriaalit
    • Usein kysytyt kysymykset
  • Asiakastarinoita
    • Unihygienia: tyynyjen ja vuodevaatteiden puhtauden seuranta
  • Messut ja tapahtumat
Suositut tuotteet
AllTest hCG pikatesti

AllTest hCG pikatesti

AllTest MONO pikatesti

AllTest MONO pikatesti

AllTest Strep A pikatesti

AllTest Strep A pikatesti

Uusimmat uutiset
Näytä kaikki

Olemme mukana Labquality Days 2025 -tapahtumassa!

22. tammikuuta 2025 | Tapahtumat

Esittelyssä QuikRead go Plus -laite!

20. tammikuuta 2025 | Uutiset, Tuoteuutiset

Increase in influenza and RSV activity in the EU/EEA

14. tammikuuta 2025 | Uutiset

  • Näytä kaikki
  • Ei tuloksia
  • Loading...
Uutiset

Olemme mukana Labquality Days 2025 -tapahtumassa!

22. tammikuuta 2025 | Tapahtumat

Esittelyssä QuikRead go Plus -laite!

20. tammikuuta 2025 | Uutiset, Tuoteuutiset

Takaisin kaikkiin uutisiin
23. elokuuta 2022
Uutiset,
AMR,
COVID-19

COVID-19 pandemic has contributed to the aggravation of Antimicrobial Resistance

Antimicrobial resistance (AMR) is an emerging health threat, but the COVID-19 pandemic set back many actions already combating AMR. Before COVID-19, Antimicrobial stewardship programs and National Actions Plans significantly progressed to slow down Antimicrobial Resistance in many countries. Due to the emergency in the healthcare systems caused by COVID-19, many planned activities were deprioritized and already integrated preventive actions were reversed1,2. For example, antibiotics were prescribed more often without diagnostic confirmation about bacterial infection than before the pandemic1,3.

Recently, the US Centers for Disease Control and Prevention reported that after several years of decrease, antimicrobial resistant hospital-onset infections and deaths increased by at least 15% during the first year of the pandemic. The change in trend indicates that AMR preventive actions must be readdressed and integrated back into the healthcare systems.

Antibiotics were commonly prescribed for hospitalized COVID-19 patients

Antibiotics do not cure viral infections, such as COVID-19, but bacterial co-infections may sometimes accompany viral infections. Treating COVID-19 patients with antibiotics, especially in the early pandemic, seemed to be rather a rule than an exception in many countries. There were concerns about bacterial co-infections, and difficulties in differentiating COVID-19 from community-acquired pneumonia that led excessive antibiotic use. In the USA and China, 80-100% of hospitalized COVID-19 patients received antibiotics1,4. However, bacterial co-infections were reported only on 7-8% of hospitalized and 14% of intensive care patients4, which suggests that antibiotics were often inappropriately used in the treatment of COVID-19.

A person holding a medicine bottle and a pill

The use of broad-spectrum antibiotics increased during COVID-19

In primary care, overall antibiotic consumption decreased in many countries during COVID-19 due to fewer visits to primary care and less spread of respiratory infection. However, the consumption of broad-spectrum antibiotics increased in the EU/EEA countries in both primary care and hospitals.5 Also, in the USA, broad-spectrum antibiotics were commonly used in hospitalized COVID-19 patients1. Broad-spectrum antibiotics are effective against a wide range of bacteria. They are not a first option treatment: they should be used only to treat severe bacterial infections. Therefore, it is necessary to use them correctly to prevent the development of resistance to these drugs.

Immediate actions are needed to optimize antibiotic use and prevent AMR

Now it is more urgent than ever to focus on AMR and reinforce antimicrobial stewardship programs to ensure the appropriate use of antibiotics and other AMR preventive actions in healthcare. Performing fast and accurate point of care tests before antibiotic prescribing, such as QuikRead go CRP and Strep A tests, are an efficient way to optimize antibiotic prescribing and prevent the development of antibiotic resistant bacteria.

Find our portfolio for CRP and Strep A point of care tests from our website: Point of care / QuikRead go


References

  1. Centers of Disease Control and Prevention (CDC). COVID-19: U.S. Impact on Antimicrobial Resistance, Special report 2022. Atlanta, GA: U.S. Department of Health and Human Services. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf
  2. Pan American Health Organization. Antimicrobial Resistance, Fueled by the COVID-19 Pandemic. Policy Brief November 2021. https://iris.paho.org/handle/10665.2/55864
  3. Mantzourani et al. To swab or not to swab? Using point-of-care tests to detect Group A Streptococcus infections as part of a Sore Throat Test and Treat service in community pharmacy. J Antimicrobial Chemoter 2021; 77:803–806.
  4. Lansbury et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;81(2):266–275.
  5. Organisation for Economic Co-operation and Development (OECD), European Centre for Disease Control and Prevention (ECDC), European Food Safety Authority (EFSA) and European Medicines Agency (EMA). Briefing note: Antimicrobial Resistance in the EU/EEA: A One Health Response. 2022.
Share
Facebook
Twitter
Sähköposti

Aidian Oy

Koivu-Mankkaan tie 6 B,
02200 Espoo
PL 83,
02101 Espoo


Vaihde
010 309 3000


Myynti
info@aidian.fi

050 380 9684


Tilaukset
tilaukset@aidian.fi
050 381 5198

Yritys
  • Tietoa meistä
  • Vastuullisuus
  • Työpaikat
  • Ota yhteyttä
Tuotteet
  • Vieritestaus
  • Mikrobiologia
  • Molekyylimikrobiologia
  • Hygieniavalvonta
  • RIA / kollageenit
  • Hengitystieinfektiot
  • Muut
Pikalinkit
  • Aidian Academy
  • Aidian Connect
  • Laitehuolto
Copyright © 2025 Aidian
  • Tietosuojakäytäntö
  • Tietosuojaseloste
  • Evästekäytäntö
  • Sosiaalisen median käytäntö